GC Biopharma Corp
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS7
PHASE 3 / 2-34
RECRUITING4
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO40%
Delay Index: of 5 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open GC Biopharma Corp on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| GC5107 NCT04565015 |
P3 | Active, not recruiting | Primary Immune Deficiency | 24 | 2026-05 (+36 mo) |
| GC3111B NCT06997627 |
P1/2 | Recruiting | Tetanus-diphtheria-acellular Pertussis (Tdap) | 120 | 2026-05 |
| Undiluted I.V.-Hepabig inj(GC5103) NCT05686759 |
P3 | Recruiting | Hepatitis B | 105 | 2026-06-30 (+19 mo) |
| MG1111 (Barycela inj.) NCT07054099 |
P3 | Recruiting | Varicella (Chickenpox); Chickenpox Vaccine | 474 | 2027-08 |
| GC4006A NCT07936188 |
P2 | Enrolling by invitation | Covid-19 Prevention | 210 | 2027-10 |
| GC3114B NCT07883928 |
P2/3 | Not yet recruiting | Influenza A, Influenza B; Influenza Vaccination | 1806 | 2028-03 |
| HM15421/GC1134A NCT06858397 |
P1/2 | Recruiting | Fabry Disesase | 18 | 2028-08-30 |